Oncotarget最新文献

筛选
英文 中文
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. 黑色素瘤中 MIF、DDT 和 CD74 的预后和治疗见解。
Oncotarget Pub Date : 2024-07-19 DOI: 10.18632/oncotarget.28615
Caroline Naomi Valdez, Gabriela Athziri Sánchez-Zuno, Lais Osmani, Wael Ibrahim, Anjela Galan, Antonietta Bacchiocchi, Ruth Halaban, Rajan P Kulkarni, Insoo Kang, Richard Bucala, Thuy Tran
{"title":"Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.","authors":"Caroline Naomi Valdez, Gabriela Athziri Sánchez-Zuno, Lais Osmani, Wael Ibrahim, Anjela Galan, Antonietta Bacchiocchi, Ruth Halaban, Rajan P Kulkarni, Insoo Kang, Richard Bucala, Thuy Tran","doi":"10.18632/oncotarget.28615","DOIUrl":"10.18632/oncotarget.28615","url":null,"abstract":"<p><p>Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a variety of cancers. Recent evidence suggests MIF as a therapeutic target in immune checkpoint inhibition (ICI) resistant melanomas, however clinical evidence of MIF and particularly of DDT remain limited. This retrospective study analyzed 97 patients treated at Yale for melanoma between 2002-2020. Bulk-RNA sequencing of patient tumor samples from the Skin Cancer SPORE Biorepository was used to evaluate for differential gene expression of MIF, DDT, CD74, and selected inflammatory markers, and gene expression was correlated with patient survival outcomes. Our findings revealed a strong correlation between MIF and DDT levels, with no statistically significant difference across common melanoma mutations and subtypes. Improved survival was associated with lower MIF and DDT levels and higher CD74:MIF and CD74:DDT levels. High CD74:DDT and CD74:MIF levels were also associated with enrichment of infiltrating inflammatory cell markers. These data suggest DDT as a novel target in immune therapy. Dual MIF and DDT blockade may provide synergistic responses in patients with melanoma, irrespective of common mutations, and may overcome ICI resistance. These markers may also provide prognostic value for further biomarker development.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"507-520"},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. 更正:阿司匹林可抵消胰腺癌的癌症干细胞特征、脱瘤和吉西他滨抗药性。
Oncotarget Pub Date : 2024-07-17 DOI: 10.18632/oncotarget.28527
Yiyao Zhang, Li Liu, Pei Fan, Nathalie Bauer, Jury Gladkich, Eduard Ryschich, Alexandr V Bazhin, Nathalia A Giese, Oliver Strobel, Thilo Hackert, Ulf Hinz, Wolfgang Gross, Franco Fortunato, Ingrid Herr
{"title":"Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.","authors":"Yiyao Zhang, Li Liu, Pei Fan, Nathalie Bauer, Jury Gladkich, Eduard Ryschich, Alexandr V Bazhin, Nathalia A Giese, Oliver Strobel, Thilo Hackert, Ulf Hinz, Wolfgang Gross, Franco Fortunato, Ingrid Herr","doi":"10.18632/oncotarget.28527","DOIUrl":"10.18632/oncotarget.28527","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"504-506"},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors. BRAF外显子15双突变纺锤形细胞肉瘤对BRAF和MEK抑制剂联合疗法反应迅速但不持久。
Oncotarget Pub Date : 2024-07-17 DOI: 10.18632/oncotarget.28606
Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova, Dmitriy Litvinov, Alexander Druy
{"title":"Rapid but nondurable response of a <i>BRAF</i> exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.","authors":"Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova, Dmitriy Litvinov, Alexander Druy","doi":"10.18632/oncotarget.28606","DOIUrl":"10.18632/oncotarget.28606","url":null,"abstract":"<p><strong>Introduction: </strong>BRAF V600E substitution predicts sensitivity of a cancer to BRAF inhibitor therapy. The mutation is rarely found in soft-tissue sarcomas. Here we describe a case of undifferentiated spindle cell sarcoma showing primary insensitivity to standard chemotherapy and pronounced but non-sustained response to BRAF/MEK inhibitors at recurrence.</p><p><strong>Case presentation: </strong>A 13-year-old girl was diagnosed with low-grade spindle cell sarcoma of pelvic localization, BRAF exon 15 double-mutated: c.1799T>A p.V600E and c.1819T>A p.S607T in cis-position. The tumor showed resistance to CWS-based first-line chemotherapy and was treated surgically by radical resection. Seven months after surgery the patient developed metastatic relapse with abdominal carcinomatosis. Combined targeted therapy with BRAF/MEK inhibitors afforded complete response in 1 month and was continued, though complicated by severe side effects (fever, rash) necessitating 1-2 week toxicity breaks. After 4 months from commencement the disease recurred and anti-BRAF/MEK regimen consolidation was unsuccessful. Intensive salvation chemotherapy was ineffective. Empirical immunotherapy afforded a transient partial response giving way to fatal progression with massive, abdominal cocoon-complicated peritoneal carcinomatosis.</p><p><strong>Conclusion: </strong>This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors. Despite the low histological grade and radical surgical treatment of the tumor at primary manifestation, the disease had aggressive clinical course and the response to BRAF/MEK targeted therapy at recurrence was complete but nondurable. Empirical use of pembrolizumab provided no unambiguous evidence on the clinical relevance of immunotherapy in protein kinase -rearranged spindle cell tumors.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"493-500"},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity. 破坏 NKG2A:HLA-E 相互作用以提高抗癌免疫力的策略。
Oncotarget Pub Date : 2024-07-17 DOI: 10.18632/oncotarget.28610
Jack G Fisher, Lara V Graham, Matthew D Blunt
{"title":"Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.","authors":"Jack G Fisher, Lara V Graham, Matthew D Blunt","doi":"10.18632/oncotarget.28610","DOIUrl":"10.18632/oncotarget.28610","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"501-503"},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the multifaceted BRAF in cancer: New directions. 靶向癌症中多方面的 BRAF:新方向。
Oncotarget Pub Date : 2024-07-16 DOI: 10.18632/oncotarget.28612
Eamon Toye, Alexander Chehrazi-Raffle, Justin Hwang, Emmanuel S Antonarakis
{"title":"Targeting the multifaceted BRAF in cancer: New directions.","authors":"Eamon Toye, Alexander Chehrazi-Raffle, Justin Hwang, Emmanuel S Antonarakis","doi":"10.18632/oncotarget.28612","DOIUrl":"10.18632/oncotarget.28612","url":null,"abstract":"<p><p>Activating mutations in the mitogen-activated protein kinase (MAPK) pathway represent driver alterations governing tumorigenesis, metastasis, and therapy resistance. MAPK activation predominantly occurs through genomic alterations in <i>RAS</i> and <i>BRAF</i>. BRAF is an effector kinase that functions downstream of <i>RAS</i> and propagates this oncogenic activity through MEK and ERK. Across cancers, <i>BRAF</i> alterations include gain-of-function mutations, copy-number alterations, and structural rearrangements. In cancer patients, BRAF-targeting precision therapeutics are effective against Class I <i>BRAF</i> alterations (p.V600 hotspot mutations) in tumors such as melanomas, thyroid cancers, and colorectal cancers. However, numerous non-Class I BRAF inhibitors are also in development and have been explored in some cancers. Here we discuss the diverse forms of <i>BRAF</i> alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"486-492"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to deal with runaway metastatic disease? 如何应对失控的转移性疾病?
Oncotarget Pub Date : 2024-07-12 DOI: 10.18632/oncotarget.28609
Justine Paris, Guilhem Bousquet
{"title":"How to deal with runaway metastatic disease?","authors":"Justine Paris, Guilhem Bousquet","doi":"10.18632/oncotarget.28609","DOIUrl":"10.18632/oncotarget.28609","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"466-467"},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death. INT-1B3是一种LNP配制的miR-193a-3p模拟物,它通过调节肿瘤微环境和诱导免疫原性细胞死亡,增强T细胞介导的免疫反应,从而促进抗肿瘤免疫。
Oncotarget Pub Date : 2024-07-12 DOI: 10.18632/oncotarget.28608
Chantal L Duurland, Thijs de Gunst, Harm C den Boer, Marion T J van den Bosch, Bryony J Telford, Rogier M Vos, Xiaolei Xie, Mingfa Zang, Fang Wang, Yingying Shao, Xiaoyu An, Jingjing Wang, Jie Cai, Ludovic Bourré, Laurens A H van Pinxteren, Roel Q J Schaapveld, Michel Janicot, Sanaz Yahyanejad
{"title":"INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.","authors":"Chantal L Duurland, Thijs de Gunst, Harm C den Boer, Marion T J van den Bosch, Bryony J Telford, Rogier M Vos, Xiaolei Xie, Mingfa Zang, Fang Wang, Yingying Shao, Xiaoyu An, Jingjing Wang, Jie Cai, Ludovic Bourré, Laurens A H van Pinxteren, Roel Q J Schaapveld, Michel Janicot, Sanaz Yahyanejad","doi":"10.18632/oncotarget.28608","DOIUrl":"10.18632/oncotarget.28608","url":null,"abstract":"<p><p>microRNAs (miRNAs) are small, non-coding RNAs that regulate expression of multiple genes. MiR-193a-3p functions as a tumor suppressor in many cancer types, but its effect on inducing specific anti-tumor immune responses is unclear. Therefore, we examined the effect of our lipid nanoparticle (LNP) formulated, chemically modified, synthetic miR-193a-3p mimic (INT-1B3) on anti-tumor immunity. INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival. INT-1B3-treated animals were fully protected against challenge with autologous tumor cells even in absence of treatment indicating long-term immunization. Protection against autologous tumor cell challenge was hampered upon T cell depletion and adoptive T cell transfer abrogated tumor growth. Transfection of tumor cells with our miR-193a-3p mimic (1B3) resulted in tumor cell death and apoptosis accompanied by increased expression of DAMPs. Co-culture of 1B3-transfected tumor cells and immature DC led to DC maturation and these mature DC were able to stimulate production of type 1 cytokines by CD4+ and CD8+ T cells. CD4-CD8- T cells also produced type 1 cytokines, even in response to 1B3-transfected tumor cells directly. Live cell imaging demonstrated PBMC-mediated cytotoxicity against 1B3-transfected tumor cells. These data demonstrate for the first time that miR-193a-3p induces long-term immunity against tumor development via modulation of the tumor microenvironment and induction of immunogenic cell death.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"470-485"},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. 更正:依赖于 Cyclin E/Cdk2 的 Mcl-1 磷酸化决定了其稳定性和细胞对 BH3 模拟物的敏感性。
Oncotarget Pub Date : 2024-07-12 DOI: 10.18632/oncotarget.28593
Gaurav S Choudhary, Trinh T Tat, Saurav Misra, Brian T Hill, Mitchell R Smith, Alexandru Almasan, Suparna Mazumder
{"title":"Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.","authors":"Gaurav S Choudhary, Trinh T Tat, Saurav Misra, Brian T Hill, Mitchell R Smith, Alexandru Almasan, Suparna Mazumder","doi":"10.18632/oncotarget.28593","DOIUrl":"10.18632/oncotarget.28593","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"468-469"},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The advances in targeting CD47/SIRPα "do not eat me" axis and their ongoing challenges as an anticancer therapy. 针对 CD47/SIRPα "别吃我 "轴的研究进展及其作为抗癌疗法所面临的挑战。
Oncotarget Pub Date : 2024-07-10 DOI: 10.18632/oncotarget.28607
Maria Gracia-Hernandez, Manasa Suresh, Alejandro Villagra
{"title":"The advances in targeting CD47/SIRPα \"do not eat me\" axis and their ongoing challenges as an anticancer therapy.","authors":"Maria Gracia-Hernandez, Manasa Suresh, Alejandro Villagra","doi":"10.18632/oncotarget.28607","DOIUrl":"10.18632/oncotarget.28607","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"462-465"},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. pembrolizumab联合可溶性EphB4-白蛋白对HPV阴性EphrinB2阳性头颈部鳞状细胞癌的疗效提高。
Oncotarget Pub Date : 2024-07-10 DOI: 10.18632/oncotarget.28605
Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King, Anthony B El-Khoueiry, Jacob Stephen Thomas, Denice Tsao-Wei, David I Quinn, Parkash S Gill, Jorge J Nieva
{"title":"Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.","authors":"Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King, Anthony B El-Khoueiry, Jacob Stephen Thomas, Denice Tsao-Wei, David I Quinn, Parkash S Gill, Jorge J Nieva","doi":"10.18632/oncotarget.28605","DOIUrl":"10.18632/oncotarget.28605","url":null,"abstract":"<p><strong>Objective: </strong>Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after primary local therapy have low response rates with cetuximab, systemic chemotherapy or check point inhibitor therapy. Novel combination therapies with the potential to improve outcomes for patients with HNSCC is an area of high unmet need.</p><p><strong>Methods: </strong>This is a phase II single-arm clinical trial of locally advanced or metastatic HNSCC patients treated with a combination of soluble EphB4-human serum albumin (sEphB4-HSA) fusion protein and pembrolizumab after platinum-based chemotherapy with up to 2 prior lines of treatment. The primary endpoints were safety and tolerability and the primary efficacy endpoint was overall response rate (ORR). Secondary endpoints included progression free survival (PFS) and overall survival (OS). HPV status and EphrinB2 expression were evaluated for outcome.</p><p><strong>Results: </strong>Twenty-five patients were enrolled. Median follow up was 40.4 months (range 9.8 - 40.4). There were 6 responders (ORR 24%). There were 5 responders in the 11 HPV-negative and EphrinB2 positive patients, (ORR 45%) with 2 of these patients achieving a complete response (CR). The median PFS in HPV-negative/EphrinB2 positive patients was 3.2 months (95% CI 1.1, 7.3). Median OS in HPV-negative/EphrinB2 positive patients was 10.9 months (95% CI 2.0, 13.7). Hypertension, transaminitis and fatigue were the most common toxicities.</p><p><strong>Discussion: </strong>The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"444-458"},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信